German G-BA looks to Bronner for the long-term
This article was originally published in Clinica
Dorothea Bronner, the chief executive at the German joint federal committee (G-BA), has been reappointed to the post for a five-year period from January 2007 until the end of 2011. Dr Bonner was also head of the forerunner of the G-BA, the co-ordination committee working group. The G-BA decides on the reimbursement of healthcare products in Germany. The reinstated head has pledged to make transparency of the G-BA's work and decision-making a priority. The G-BA oversees IQWIG, its executive arm, which carries out the HTA function.
You may also be interested in...
US investigators fan out to non-China inspection priorities and Secretary Azar talks supply management; warning letters hit record keeping, investigations and basic GMP compliance.
Mallinckrodt to pay $1.6bn and place its generics unit in bankruptcy under agreement in principle for US global settlement; six states are not on board, including New York, whose suit is still set to go to trial March 20.
The company has reached a broad opioid settlement agreement in principle under which its specialty generics subsidiaries would file for Chapter 11 bankruptcy and Mallinckrodt's branded business would operate separately.